Table 3.
Mortality during follow-up by history of LEA at baseline
| All-cause mortality | Cardiovascular mortality | Infectious disease mortality | Other causes of mortality | |||||
|---|---|---|---|---|---|---|---|---|
| No | Yes | No | Yes | No | Yes | No | Yes | |
| LEA at baseline | ||||||||
| No | 691 (93.6 %) | 47 (6.4 %) | 691 (97.5 %) | 18 (2.5 %) | 691 (99.0 %) | 7 (1.0 %) | 691 (96.9 %) | 22 (3.1 %) |
| Yes | 36 (59.0 %) | 25 (41.0 %) | 36 (78.3 %) | 10 (21.7 %) | 36 (92.3 %) | 3 (7.7 %) | 36 (75.0 %) | 12 (25.0 %) |
| HR (95 % CI) model 1 | 3.55 (2.05–6.16) | 4.04 (1.69–9.62) | 3.28 (0.73 –14.68) | 3.25 (1.44–7.30) | ||||
| P | <0.0001 | 0.002 | 0.12 | 0.004 | ||||
| HR (95 % CI) model 2 | 2.73 (1.49–5.01) | 3.30 (1.36–8.02) | 5.18 (1.13–23.84) | 2.81 (1.09–7.26) | ||||
| P | 0.001 | 0.008 | 0.03 | 0.03 | ||||
Data expressed as number of cases and (%) by line. Hazards ratio (HR) for a positive LEA history at baseline as a risk for all-cause mortality, cardiovascular, infectious disease, and other causes of mortality during follow-up, computed by Cox proportional hazards survival regressive analysis. Model 1: adjusted for cohort membership, sex and age at baseline. Model 2: adjusted for cohort membership, sex, age, duration of diabetes, HbA1c, UAC, eGFR, use of antihypertensive and lipids lowering drugs, and history of tobacco smoking
p < 0.05 is significant